
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form

SPMS is a debilitating stage of MS where patients experience increasing levels of disability

Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

The data underlines the consequences of disrupted sleep for patients and caregivers

The treatment can be used to delay the onset of clinical type 1 diabetes

EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.

There are currently no approved treatments for the neurological symptoms of this disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

Newly released study data shows consistent reductions in disease severity

The study demonstrated a sustained reduction in seizures for patients